



Ironwood Pharmaceuticals, Inc.
Investor Relations Department
301 Binney Street, 2nd floor
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: IRWD ¹

Last Trade:	17.48
Trade Time:	2:14 PM ET May 23, 2018
Change:	0.00 (0.000%)
Day Range	17.37 - 17.69
52-Week Range	12.89 - 19.94
Volume	430,587
Market Cap. (\$M)	2,650.318
Shares Out (M)	151.620

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

At Ironwood, we're focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 23, 2018

[Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease \(GERD\) at Digestive Disease Week® 2018](#)

May 14, 2018

[Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees](#)

May 9, 2018

[Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value](#)

May 3, 2018

[Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® \(linaclotide\) Patent Litigation](#)

May 2, 2018

[Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

May 4, 2018

[Quarterly Report \(10-Q\)](#)